-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia and is relatively rare in the pediatric population.
It is relatively rare in the pediatric population.
This is a multi-center clinical trial conducted in 38 hospitals in China, recruiting newly diagnosed APL patients, and dividing the tested patients into two risk groups based on the basic WBC count and FLT3-TID mutation.
A and B: overall survival rate; C and D: event-free survival rate; E and F: cumulative recurrence rate
A and B: overall survival rate; C and D: event-free survival rate; E and F: cumulative recurrence rateA total of 193 APL patients were recruited.
After a median follow-up of 28.
In summary, arsenic combined with ATRA is effective and safe for children with APL , but long-term follow-up is still needed .
Arsenic combined with ATRA is effective and safe for children with APL , but long-term follow-up is still required.
Original source:
Huyong Zheng, et al.
Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study
in this message